



Expert UK-based CRO offering customised bioassay development, pharmacological profiling and compound screening


### Welcome to the latest edition of our newsletter

It is an exciting time for Aurelia Bioscience as our clients continue to explore novel ways to increase productivity and success rates of new therapeutic compound discovery. Our dedicated team of scientists have been working very closely with them through the multiple stages of early drug discovery, helping them discover the next breakthrough drug!

### Attention Kinase Lovers!

Our Chief Scientific Officer, Dr. Gary Allenby has written a very interesting article for Drug Discovery World on 'Kinases- Old Dogs and New Tricks- Applications of New Assay Technologies to Shed Light on Kinase Drug Discovery'.

The human kinome comprises 518 known protein kinases and more than 20 lipid kinases. Nearly all aspects of control within a cell are modulated by reversible phosphorylation of proteins, mediated by protein kinases. Abnormal phosphorylation is a cause or effect of several diseases including cancer and inflammatory diseases and has therefore generated a lot of interest in the pharmaceutical and biotech industries. [Follow the link to read the full article: http://bit.ly/2vrQKeu](http://bit.ly/2vrQKeu)



### Have you watched our video yet?


Seeing is believing! We are pleased to bring to you our official video, highlighting our services and capabilities. With decades of experience and the use of cutting- edge technologies, we can help develop bioassays for reliable compound progression, to benefit all stages of early drug discovery research: <http://bit.ly/2M5dmLy>



## Application of novel 3-dimensional electro spun micro-scaffold technology as a drug discovery platform for cell biology

Below is an excerpt from our Chief Scientific Officer, Gary Allenby's talk on '3-D electro spun micro-scaffolding technology' at the ACTC conference held in Cardiff recently.

"In an effort to create a more physiologically relevant environment for cell growth, while maintaining the logistics of well plate screening throughput, we have developed a three-dimensional micro-scaffold from electro spun material that can be used in conjunction with well plates for higher throughput screening. We have re-engineered electro spun material to form micro-scaffold islands on to which we seed, grow and differentiate cells prior to performing more conventional assays in well plates. Cells grow on, around and into the material, forming a micro-island of adherent cells that are effectively "in solution". The incorporation of iron nano-particles into the fibres during manufacture results in micro-scaffolds that can be physically manipulated using magnetism. We can therefore maintain islands of cells in media within the incubator in a tube, moving these up and down using magnetism. We also manipulate micro-scaffolds within wells using arrays of magnets, attracting scaffolds to the edges of wells to prevent damage during media replacement or align scaffolds in the centre of wells for imaging purposes. Using sheathed magnets, we can move micro-scaffolds from well to well with no adverse effects to cells. In addition, we have incorporated fluorescent dyes or quantum dots into the fibres during manufacture such that fibres can be visualised using fluorescence microscopy, while quantum dots can be used as a barcode to distinguish between two cell populations on different scaffolds within the same well." [Get in touch with Gary to find out more about our work with 3D technology: allenby@areliabio.com](mailto:allenby@areliabio.com)



### OBN awards 2018:

We are delighted to have been nominated by our clients for the 2018 OBN award for Best Specialist CRO. The award ceremony will be held in Oxford in October.

### Upcoming events:

Catch us at the following events this quarter if you are attending as well!

#### [7th RSC / SCI Symposium on GPCRs in Medicinal Chemistry](#)

Verona, Italy • September 10-12

#### [The Best of Both Worlds: Innovation, Collaboration and Synergy between CROs and their Client Partners](#)

Stevenage, UK • September 26

### Contact Information:

Aurelia Bioscience  
BioCity Nottingham,  
Pennyfoot Street  
Nottingham NG1 1GF  
United Kingdom

Phone: +44 (0)115 837 0503

Email: [info@areliabio.com](mailto:info@areliabio.com)

Web: [www.aureliabio.com](http://www.aureliabio.com)